PLoS Genetics (Apr 2022)

Heteroplasmic mitochondrial DNA variants in cardiovascular diseases.

  • Claudia Calabrese,
  • Angela Pyle,
  • Helen Griffin,
  • Jonathan Coxhead,
  • Rafiqul Hussain,
  • Peter S Braund,
  • Linxin Li,
  • Annette Burgess,
  • Patricia B Munroe,
  • Louis Little,
  • Helen R Warren,
  • Claudia Cabrera,
  • Alistair Hall,
  • Mark J Caulfield,
  • Peter M Rothwell,
  • Nilesh J Samani,
  • Gavin Hudson,
  • Patrick F Chinnery

DOI
https://doi.org/10.1371/journal.pgen.1010068
Journal volume & issue
Vol. 18, no. 4
p. e1010068

Abstract

Read online

Mitochondria are implicated in the pathogenesis of cardiovascular diseases (CVDs) but the reasons for this are not well understood. Maternally-inherited population variants of mitochondrial DNA (mtDNA) which affect all mtDNA molecules (homoplasmic) are associated with cardiometabolic traits and the risk of developing cardiovascular disease. However, it is not known whether mtDNA mutations only affecting a proportion of mtDNA molecules (heteroplasmic) also play a role. To address this question, we performed a high-depth (~1000-fold) mtDNA sequencing of blood DNA in 1,399 individuals with hypertension (HTN), 1,946 with ischemic heart disease (IHD), 2,146 with ischemic stroke (IS), and 723 healthy controls. We show that the per individual burden of heteroplasmic single nucleotide variants (mtSNVs) increases with age. The age-effect was stronger for low-level heteroplasmies (heteroplasmic fraction, HF, 5-10%), likely reflecting acquired somatic events based on trinucleotide mutational signatures. After correcting for age and other confounders, intermediate heteroplasmies (HF 10-95%) were more common in hypertension, particularly involving non-synonymous variants altering the amino acid sequence of essential respiratory chain proteins. These findings raise the possibility that heteroplasmic mtSNVs play a role in the pathophysiology of hypertension.